Evidence review
What You Are Actually Buying When a Compounded GLP-1 Costs $99
A compounded GLP-1 price is set by federal compounding rules before it is set by anything else. What the FDA allows in 2026, and what it does to the number.
Compounded semaglutide sells for $99 a month while the branded pen sells for several hundred. That gap is real, and the reason for it is not chemistry. It is a set of federal rules about who may compound what, when, and how many times — rules that changed twice in April 2026 and are still moving. This is what actually sets the price.
Compounded means not FDA-approved, and the FDA says so plainly
The agency's own language is unhedged: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."1 There is no approval file, no premarket review of that specific product, and no bioequivalence study behind the vial.
That absence is a cost structure. A branded GLP-1 carries the amortised price of clinical trials, an approval, and post-market commitments. A compounded one does not. Most of what you are buying when you buy the cheaper option is the absence of that overhead — which is a legitimate reason for a lower price and also the whole of the trade-off.
Two legal doorways, and only one of them is open
Federal law recognises two routes. Section 503A covers a licensed pharmacist compounding for an individual patient in a state-licensed pharmacy. Section 503B covers outsourcing facilities, a category created in 2013 that registers with the FDA, is inspected on a risk-based schedule, and must meet current good manufacturing practice requirements.1 We break the price consequences of that split down in 503A or 503B: which kind of pharmacy filled your vial.
For GLP-1s specifically, both doorways narrowed. Compounders could work at scale while semaglutide and tirzepatide sat on the FDA's drug shortage list. Both shortages were declared resolved — tirzepatide in December 2024, semaglutide in February 2025 — and the enforcement-discretion windows that followed have all closed.2
The rule that decides whether a compounded GLP-1 can exist at all
Under 503A, a compounder may not regularly compound products that are "essentially copies of a commercially available drug product." The FDA restated in April 2026 what it counts as a copy: same active ingredient as the commercial product, in "the same, similar or an easily substitutable strength," usable by the same route of administration — unless a prescriber documents that the compounded version contains a change producing a significant difference for that individual patient.2
Read that carefully, because it is the pricing mechanism. The exception is not a category. It is a per-patient, per-prescription, documented clinical determination. Any business model that treats it as a category is exposed.
Four prescriptions a month
The FDA also stated the threshold it is currently working to: it "does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month."2
Four. Per compounder, per product, per calendar month. That is a statement of enforcement intent rather than a licence, and it is nowhere near the volume a national telehealth brand ships. If a seller is quoting you a compounded GLP-1 as a standing monthly subscription, the arithmetic of that sentence is worth holding in your head.
Why so many compounded vials have a vitamin in them
You will have noticed that compounded GLP-1s are frequently sold with something added — B12, B6, an amino acid. The FDA addressed exactly that combination in the same April 2026 statement, and it did not accept it as a distinction:
The agency said it may consider a product combining semaglutide and another ingredient such as vitamin B12 to be essentially a copy where the products are used by the same route of administration and the amounts of each ingredient are within 10% of the strengths of the respective commercially available products.2
So an added vitamin is not, on the FDA's stated reading, automatically a "significant difference." Treat a combination product as a pricing and marketing decision unless the prescriber has documented a clinical reason specific to you.
The outsourcing-facility route, and the proposal that would close it
Outsourcing facilities generally cannot compound from a bulk drug substance unless that substance is on the 503B bulks list, or the finished drug is on the shortage list at the time of compounding.2 Neither semaglutide nor tirzepatide is on either list.
On 30 April 2026 the FDA went further and proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list outright, saying it "did not identify a clinical need for outsourcing facilities to compound these drugs from bulk drug substances." Comments were invited through 29 June 2026, and the agency said it would consider them before a final determination.3 As of August 2026 that determination has not been published.
What this does to a price you are quoted today
Three practical consequences, none of them clinical.
A low compounded price is not a durable price. It rests on a regulatory position that moved twice in one month this year. Nothing about the number you are quoted in August obliges anyone to honour it in December.
A "personalised" formulation may not be doing the legal work the seller implies. See the vitamin paragraph above.
And the supply chain is checkable. The FDA publishes the full list of registered outsourcing facilities, updated weekly, with each facility's registration dates, last inspection date, whether a Form 483 was issued and whether a recall was conducted.4 If a seller names its pharmacy, you can look it up in about a minute. If it will not name one, that is the finding.
What the sellers themselves publish
Strut Health lists compounded oral semaglutide at $99 for a 30-day supply and states on the page that the "price includes physician consultations and free shipping" — one charge, no membership stacked underneath it.5 Mochi Health prices the medication and the membership as two separate subscriptions, with the drug page saying the cost of medication is not included in the membership fee.6 Both were read on 7 August 2026.
Same category, same molecule class, two entirely different bill shapes. Compare current compounded pricing on our compounded semaglutide board and compounded tirzepatide board, and see how a single seller's number is assembled in our Strut Health review and Mochi Health review.
Frequently asked questions
Why is compounded semaglutide so much cheaper than the branded pen?
Because a compounded product carries none of the cost of an approval. The FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed, and there is no clinical trial programme behind that specific vial. That is a real cost difference, and it is also the entire trade-off — you are buying the absence of the review, not a discount on the same product.
Is compounded semaglutide still legal in 2026?
Compounding itself is legal; compounding a copy of a commercially available drug at scale is the constrained part. The semaglutide and tirzepatide shortages were declared resolved in February 2025 and December 2024, and every enforcement-discretion window that followed has closed. The FDA said in April 2026 that it does not intend to act against a compounder filling four or fewer prescriptions of an essentially-a-copy product per calendar month. Neither drug appears on the 503B bulks list, and in April 2026 the FDA proposed excluding both from it permanently.
Does adding B12 or B6 make a compounded GLP-1 a different drug?
Not automatically, on the FDA's own stated reading. In April 2026 the agency used a semaglutide-plus-B12 product as its worked example of something it may still consider essentially a copy, where the route of administration matches and the ingredient amounts are within 10% of the commercially available strengths. The exception in the rule is a documented, patient-specific prescriber determination — not the presence of an added ingredient.
How do I find out which pharmacy is actually making my medication?
Ask the seller to name it, then check it. The FDA publishes the full list of registered 503B outsourcing facilities weekly, including each facility's inspection date, whether a Form 483 was issued and whether it conducted a recall. A state-licensed 503A pharmacy will not appear on that list — it is overseen by its state board of pharmacy instead. A seller that will not name the pharmacy at all has told you something.
References
- US Food and Drug Administration (2026). Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- US Food and Drug Administration (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (statement dated 1 April 2026). FDA Drug Alerts and Statements. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- US Food and Drug Administration (2026). FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (30 April 2026). FDA Press Announcements. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- US Food and Drug Administration (2026). Facilities Registered as Human Drug Compounding Outsourcing Facilities Under Section 503B (updated 4 August 2026). FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Strut Health, LLC (2026). Compounded oral semaglutide product page (read 7 August 2026). struthealth.com. https://www.struthealth.com/weight-loss/semaglutide/oral
- Mochi Health Corp. (2026). Compounded semaglutide product page (read 7 August 2026). joinmochi.com. https://joinmochi.com/medications/compounded-semaglutide
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
“Covered” Is Not a Price: What Your Plan Has Actually Promised
Covered means a drug is on a list. It does not mean a price, a fill, or a device. The four gates between a formulary entry and a dispensed prescription.
ReadCopay Cards: The Cap Is the Product
“Pay as little as $25” is a floor, not a price. What the manufacturer caps, who is excluded by name, and why card spending never touches your deductible.
ReadA $169 Month That Costs $2,028 on Day One
The “/mo” in a GLP-1 headline is often a division, not a charge. Four live prepay structures, the arithmetic behind each, and which discount badges survive it.
ReadThirteen Charges, Twelve Months
A year holds 13 four-week blocks, not 12. Four live billing patterns in GLP-1 care, the remainder each one creates, and how to tell which one you are on.
ReadWhat a GLP-1 Membership Fee Actually Buys
Most GLP-1 telehealth bills have two lines, and the membership is the one that moves. Four operators, four different definitions, and how to price the fee.
ReadWhy Your Second Refill Costs More Than Your First
Three mechanisms move a GLP-1 price between fill one and fill two, and they stack. What each looks like, and how to price month two before you buy month one.
Read503A or 503B: Which Kind of Pharmacy Filled Your Vial
Two legal categories hide behind one word on an invoice. What the FDA says separates them, which costs more to run, and why only one is publicly checkable.
ReadCash-Pay or Insurance: The Number That Decides It
Not price against price. Cash spending and covered spending fill different ledgers, and only one has a ceiling. Where the crossover actually sits.
ReadHow to Read a GLP-1 Provider's Pricing Page
Six questions the headline number has to answer before it means anything, run against three real pricing pages — and the two-line test that settles the rest.
ReadZepbound vs Wegovy: Which Is Cheaper Depends on Who Is Buying
Cash-pay, Zepbound costs $100 a month more than Wegovy. At what pharmacies pay to stock them, Wegovy costs $254 more. Both figures are first-party.
ReadMounjaro vs Ozempic: One Flat Price Against a Four-Step Ladder
Lilly charges $499 for every Mounjaro dose. Novo charges $149 to $499 for Ozempic depending on dose and form. Where the two lines cross, with the arithmetic.
ReadCompounded Semaglutide vs Branded Wegovy: The Gap Has Nearly Closed
A year of branded Wegovy tablets from Novo costs $3,338. A year of compounded semaglutide at two major sellers costs more. Priced from first-party pages.
ReadCompounded Tirzepatide vs Branded Zepbound: They Now Collide at $449
One compounded tirzepatide plan charges $449 a month. LillyDirect charges $449 for the FDA-approved drug. What actually sets the price is the layer in between.
ReadWhat LillyDirect Actually Costs, Product by Product
LillyDirect lists eleven medicines and publishes a self-pay price for three. Every figure, plus the two different definitions of a month on the same site.
ReadWhat NovoCare Pharmacy Actually Costs, Dose by Dose
Novo prices every Wegovy and Ozempic dose it sells. The traps are two different expiry dates, a $100 ceiling on the $25 offer, and what cash-pay does to Part D.
ReadOral Semaglutide: What the Tablet Costs Against the Pen
Novo's semaglutide tablet costs about $900 a year less than the pen. Pharmacies pay within five dollars of the same for both. The gap is a pricing decision.
ReadSwitching From Compounded to Branded: How Big the Step Really Is
Switching is not one price replacing another. Four charges change at once, and the introductory price you were counting on is usually out of reach.
ReadGLP-1 Costs by Dose: Does Titrating Up Actually Cost More?
Four different pricing philosophies are live at once. And on CMS acquisition data, a higher dose costs more in exactly one product out of every one we checked.
ReadWhat Happens to Your Price When You Reach Maintenance
Every branded GLP-1 we priced rises 50% to 151% between the first fill and the plateau — and the introductory offer expires on the fill you titrate past it.
ReadGeneric Liraglutide: The Cheapest GLP-1 Almost Nobody Prices
Nine liraglutide generics are approved. One 30-day carton costs a pharmacy $288.20 — against $1,306.72 for a month of Wegovy pens. The catches are real.
ReadThe True Cost of Stopping and Restarting a GLP-1
Stopping is free. Restarting costs you the introductory price, the refill window, and anything you prepaid — five mechanisms, each with a number attached.
Read